{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:19:15Z","timestamp":1783063155299,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574262"],"award-info":[{"award-number":["82574262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304310"],"award-info":[{"award-number":["82304310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22363002"],"award-info":[{"award-number":["22363002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejmech.2026.118912","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:42:11Z","timestamp":1778049731000},"page":"118912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design of fibroblast growth factor receptor (FGFR) inhibitors containing a 3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one motif"],"prefix":"10.1016","volume":"314","author":[{"given":"Yuanli","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-0431","authenticated-orcid":false,"given":"Silong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2026.118912_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.367","article-title":"FGFR families: biological functions and therapeutic interventions in tumors","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118912_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116845","article-title":"Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: their roles, mechanisms and challenges","volume":"235","author":"Luo","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118912_bib3","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1021\/acs.jmedchem.1c01977","article-title":"Discovery of 1,6-Naphthyridin-2(1H)-one derivatives as novel, potent, and selective FGFR4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118912_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117339","article-title":"Discovery of BW710 as a potent, selective and orally bioavailable fibroblast growth factor receptor 2 (FGFR2) inhibitor","volume":"287","author":"Yang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118912_bib5","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1021\/acs.jmedchem.2c01507","article-title":"Structural optimization of fibroblast growth factor receptor inhibitors for treating solid tumors","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118912_bib6","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/acs.jmedchem.5c02462","article-title":"Design, synthesis, and biological evaluation of the first novel macrocycle-based FGFR inhibitors that overcome clinically acquired resistance","volume":"69","author":"Xiang","year":"2026","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118912_bib7","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.jmedchem.3c02040","article-title":"Identification of Piperazinyl\u2013difluoro-indene derivatives containing pyridyl groups as potent FGFR inhibitors against FGFR mutant tumor: design, synthesis, and biological evaluation","volume":"67","author":"Ding","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118912_bib8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective Pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118912_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10637-018-0648-z","article-title":"A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor","volume":"37","author":"Kelly","year":"2018","journal-title":"Invest. N. Drugs"},{"issue":"20","key":"10.1016\/j.ejmech.2026.118912_bib10","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118912_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115955","article-title":"FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1","volume":"170","author":"Guo","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118912_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114566","article-title":"FGFR signaling and neddylation facilitate SARS-CoV-2 infection by modulating interferon induction and viral entry, respectively","volume":"29","author":"Felix-Lopez","year":"2026","journal-title":"iScience"},{"issue":"19","key":"10.1016\/j.ejmech.2026.118912_bib13","doi-asserted-by":"crossref","first-page":"13158","DOI":"10.1021\/acs.jmedchem.2c00986","article-title":"Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS-driven carcinoma","volume":"65","author":"He","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118912_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117206","article-title":"Design, synthesis, and biological evaluation of Ponatinib-based N-Phenylpyrimidine-2-amine derivatives as novel fibroblast growth factor receptor 4 (FGFR4) selective inhibitors","volume":"284","author":"Han","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118912_bib15","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1021\/acs.jmedchem.5c00490","article-title":"Rational design of methylene blue\u2013raloxifene conjugates for efficient breast tumor elimination triggered by ER\u03b1 degradation","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"42","key":"10.1016\/j.ejmech.2026.118912_bib16","doi-asserted-by":"crossref","first-page":"28685","DOI":"10.1021\/jacs.4c04648","article-title":"Molecular dynamics unveils multiple-site binding of inhibitors with reduced activity on the surface of dihydrofolate reductase","volume":"146","author":"Araki","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118912_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jcc.70093","article-title":"Enhancing MM\/P(G)BSA methods: integration of formulaic entropy for improved binding free energy calculations","volume":"46","author":"Dong","year":"2025","journal-title":"J. Comput. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118912_bib18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1080\/07391102.2022.2032355","article-title":"Deciphering the molecular mechanisms of selective non-covalency demonstrated differentially by 9-Allylnaphtho[1,8-ef]isoindole-7,8,10(9H)-trione (C11) against fibroblast growth factor receptors 1\u20134","volume":"41","author":"Olotu","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118912_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf128","article-title":"Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities","volume":"53","author":"Katopodi","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/1673-5374.374135","article-title":"Transcriptomic and bioinformatics analysis of the mechanism by which erythropoietin promotes recovery from traumatic brain injury in mice","volume":"19","author":"Tan","year":"2024","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib21","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-025-61820-z","article-title":"A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas","volume":"16","author":"Apfelbaum","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40478-025-02025-9","article-title":"Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors","volume":"13","author":"Martinez-Mendoza","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12672-024-01363-9","article-title":"Identification of key ferroptosis genes and subtypes in kidney renal clear cell carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10565-025-10025-7","article-title":"Lipotoxicity, lipid peroxidation and ferroptosis: a dilemma in cancer therapy","volume":"41","author":"Ma","year":"2025","journal-title":"Cell Biol. Toxicol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118912_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10555-025-10274-2","article-title":"Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates","volume":"44","author":"Kim","year":"2025","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acs.jmedchem.3c01770","article-title":"Identification of a sonically activated degrader of methionine adenosyltransferase 2A by an in Silico approach assisted with the hole\u2013electron analysis","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118912_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202500179","article-title":"Fibronectin\u2010functionalized tea polyphenol nanoparticles loaded with Ferrostatin\u20101 for synergistic abdominal aortic aneurysms therapy","volume":"8","author":"Zhang","year":"2025","journal-title":"Adv. Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118912_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13287-025-04263-z","article-title":"Ferrostatin-1 inhibits tracheal basal cell ferroptosis to facilitate the rapid epithelization of 3D-printed tissue-engineered tracheas","volume":"16","author":"Li","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ejmech.2026.118912_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176528","article-title":"Protecting against ferroptosis in hyperuricemic nephropathy: the potential of ferrostatin-1 and its inhibitory effect on URAT1","volume":"971","author":"Li","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118912_bib30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1021\/acs.jmedchem.4c02269","article-title":"Discovery of D-Ring-Contracted artemisinin as a potent hydrophobic tag for targeted protein degradation","volume":"68","author":"Qing","year":"2025","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118912_bib31","doi-asserted-by":"crossref","first-page":"19415","DOI":"10.1021\/acs.jmedchem.5c01594","article-title":"Design, synthesis and biological evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine derivatives as novel covalent pan-FGFR inhibitors to overcome clinical resistance","volume":"68","author":"Deng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118912_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116612","article-title":"Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor","volume":"275","author":"Hu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118912_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202412578","article-title":"Integrative multi\u2010omics approaches reveal selectivity profiles and molecular mechanisms of FIIN\u20102, a covalent FGFR inhibitor","volume":"12","author":"Fu","year":"2025","journal-title":"Adv. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426003570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:52:27Z","timestamp":1783061547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426003570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S0223523426003570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118912","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of fibroblast growth factor receptor (FGFR) inhibitors containing a 3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one motif","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118912"}}